Effect of Sodium Alginate on Acid Gastroesophageal Reflux Disease in Preterm Infants: A Pilot Study

2010 ◽  
Vol 50 (11) ◽  
pp. 1267-1272 ◽  
Author(s):  
Begum Atasay ◽  
Omer Erdeve ◽  
Saadet Arsan ◽  
Tomris Türmen
Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1813
Author(s):  
Jeffrey M. Beckett ◽  
Neeraj K. Singh ◽  
Jehan Phillips ◽  
Krishnakumar Kalpurath ◽  
Kent Taylor ◽  
...  

Gastroesophageal reflux disease (GERD) affects approximately 20% of Australians. Patients suffer a burning sensation known as heartburn due to the movement of acidic stomach content into the esophagus. There is anecdotal evidence of the effectiveness of prebiotic sugarcane flour in controlling symptoms of GERD. This pilot study aimed to investigate the effectiveness of a prebiotic sugarcane flour in alleviating symptoms in medically-diagnosed GERD patients. This pilot study was a single center, double-blinded, placebo-controlled randomized trial conducted on 43 eligible participants. The intervention group (n = 22) were randomized to receive 3 g of sugarcane flour per day, and the control group (n = 21) received 3 g of cellulose placebo per day. Symptoms of gastroesophageal reflux disease were assessed before and after three weeks treatment using the validated Gastroesophageal Reflux Disease-Health Related Quality of Life questionnaire (GERD-HRQL). After three weeks there were significant differences in symptoms for heartburn, regurgitation, and total symptoms scores (p < 0.05) between the sugarcane flour and placebo. Mean GERD-HRQL scores increased in the placebo group for regurgitation (mean increase 1.7; 95% CI 0.23 to 3.2; p = 0.015) and total symptom scores (2.9; 95% CI 0.26 to 5.7; p = 0.033). In contrast, there were significant reductions in heartburn (mean decrease −2.2; 95% CI −4.2 to −0.14; p = 0.037) and total symptom scores (−3.7; 95% CI −7.2 to −0.11; p = 0.044) in the intervention group. This pilot study has shown significant positive effects of sugarcane flour in the reduction of GERD symptoms, and a larger randomized controlled trial is warranted.


2009 ◽  
Vol 155 (2) ◽  
pp. 222-228 ◽  
Author(s):  
Taher Omari ◽  
Per Lundborg ◽  
Marie Sandström ◽  
Patrik Bondarov ◽  
Mia Fjellman ◽  
...  

2016 ◽  
Vol 111 ◽  
pp. S454
Author(s):  
Mario Blancas ◽  
Monica Hidalgo ◽  
Ruben Martinez ◽  
Claudia Blanco ◽  
Alejandro Angeles ◽  
...  

2021 ◽  
pp. 109980042098788
Author(s):  
Colleen E. Shelly ◽  
Evgenia J. Filatava ◽  
Julie Thai ◽  
Britt F. Pados ◽  
Sara E. Rostas ◽  
...  

Objectives: Reflux is common in infancy; however, persistent signs and symptoms of gastrointestinal distress are often attributed to gastroesophageal reflux disease (GERD). In this pilot study, we aimed to characterize associations between signs and symptoms of suspected GERD and noninvasive markers of intestinal inflammation in preterm infants. Methods: We reviewed Electronic Medical Record (EMR) data to identify clinical signs and symptoms among case patients (n = 16). Controls (n = 16) were matched on gestational age. Univariate and multivariate regression analyses were used to compare fecal calprotectin and urinary intestinal fatty acid binding protein (I-FABP) levels between cases and controls. Results: We found no differences in baseline characteristics between cases and controls. In the multivariate regression analysis controlling for the proportion of mother’s milk, cases had higher fecal calprotectin levels than controls, with no differences in I-FABP levels between cases and controls. Conclusion: Our findings suggest that preterm infants with signs and symptoms of GERD have higher levels of intestinal inflammation as indicated by fecal calprotectin compared to their controls. Further studies are needed to evaluate the role of intestinal inflammation in signs and symptoms of gastrointestinal distress and whether fecal calprotectin might have predictive value in diagnosing GERD.


Sign in / Sign up

Export Citation Format

Share Document